Table 2.
Comparisons of SSHL patients with and without improvement following standard treatment protocol
| Parameter | Improved patients (N: 102) | Patients without improvement (N: 45) | P |
|---|---|---|---|
| Age range (year) | 15–54 | 15–55 | – |
| Mean age (year) | 28.77 ± 9.58 | 29.26 ± 9.62 | .633 |
| Gender (M/F) | 55/47 | 24/21 | – |
| Treatment onset (day) | 1–8 (3.96 ± 3.62) | 1–20 (10.24 ± 8.12) | .002* |
| MCV (femtoliter) | 83.15 ± 8.33 | 86.12 ± 7.11 | .232 |
| Hemoglobin (g/dl) | 13.94 ± 1.60 | 13.48 ± 1.25 | .455 |
| Hematocrit (%) | 41.25 ± 4.23 | 39.84 ± 4.17 | .288 |
| RDW (%) | 13.60 ± 1.68 | 13.19 ± 1.10 | .452 |
| WBC (103/μl) | 8.21 ± 2.07 | 8.92 ± 2.39 | .507 |
| Platelet (103/μl) | 252.39 ± 55.17 | 269.13 ± 64.92 | .397 |
| Total bilirubin (mg/dl) | 0.59 ± 0.28 | 0.45 ± 0.13 | .143 |
| Direct bilirubin (mg/dl) | 0.20 ± 0.13 | 0.19 ± 0.10 | .841 |
| Indirect bilirubin (mg/dl) | 0.40 ± 0.26 | 0.33 ± 0.13 | .097 |
| Fasting blood glucose (mg/dl) | 110.02 ± 50.25 | 114.24 ± 58.40 | .856 |
| BUN (mg/dl) | 18.98 ± 8.12 | 16.75 ± 8.28 | .485 |
| Creatinin (mg/dl) | 0.91 ± 0.37 | 1.25 ± 0.65 | .424 |
| Total lipid (mg/dl) | 170.12 ± 43.23 | 182.67 ± 33.14 | .482 |
| Triglyceride (mg/dl) | 175.44 ± 80.59 | 188.13 ± 60.44 | .652 |
| HDL (mg/dl) | 41.52 ± 13.25 | 44.74 ± 12.81 | .787 |
| LDL (mg/dl) | 91.43 ± 24.81 | 110.62 ± 37.25 | .275 |
| VLDL (mg/dl) | 38.71 ± 14.70 | 35.61 ± 14.23 | .814 |
| AST (u/l) | 26.13 ± 8.12 | 24.81 ± 10.41 | .421 |
| ALT (u/l) | 24.29 ± 10.50 | 26.27 ± 15.08 | .757 |
MCV mean corpuscular volume, RDW red cell distribution width, WBC white blood cell count, BUN blood urea nitrogen, HDL high density lipoprotein, LDL low density lipoprotein, VLDL very low density lipoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase
* Statistically significant